PISCATAWAY, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its fourth-quarter and full-year 2010 financial results. For the three months ended December 31, 2010, Enzon reported a loss from continuing operations of $10.4 million or $0.17 per diluted share, as compared to a loss from continuing operations of $14.6 million or $0.32 per diluted share for the fourth quarter of 2009. For the full year ended December 31, 2010, Enzon reported a loss from continuing operations of $3.6 million or $0.06 per diluted share, compared to a loss from continuing operations of $57.2 million or $1.26 per diluted share for the full year ended December 31, 2009.
